Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Virucidal effect of myeloperoxidase on human-immunodeficiency-virus type 1-infected t-cells

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Chochola, J.
  • Yamaguchi, Y.
  • Moguilevsky, N.
  • Bollen, A.
  • Strosberg, Donny
  • Stanislawski, M.

publication date

  • May 1994

journal

  • Antimicrobial Agents and Chemotherapy  Journal

abstract

  • Myeloperoxidase is virucidal to human immunodeficiency virus type 1 (HIV-1) in the persistently infected CEM human T-cell line or in acutely infected human peripheral blood mononuclear cells, as judged by viral infectivity and P24 radioimmunoassay. HIV-1 was specifically inactivated by low doses of the human myeloperoxidase (1.4 to 14.3 mU/ml) and the cells were spared. A higher enzyme concentration (143 mU/m) was cytotoxic, but uninfected CEM cells and normal lymphocytes were resistant to > or = 143 mU of myeloperoxidase per ml. The enzyme was virucidal with the Cl- present in medium and did not require exogenous H2O2. Catalase, an antioxidant enzyme, partially inhibited the virucidal effect of myeloperoxidase. Hence, the H2O2 probably came from the HIV-infected cells themselves. These in vitro findings indicate that the myeloperoxidase system is capable of inactivating HIV-1 of infected cells.

subject areas

  • Antiviral Agents
  • Catalase
  • Cell Line
  • Glucose Oxidase
  • HIV Core Protein p24
  • HIV-1
  • Humans
  • Lactoperoxidase
  • Peroxidase
  • Phytohemagglutinins
  • Radioimmunoassay
  • T-Lymphocytes
scroll to property group menus

Identity

PubMed Central ID

  • PMC188135

International Standard Serial Number (ISSN)

  • 0066-4804

PubMed ID

  • 8067778
scroll to property group menus

Additional Document Info

start page

  • 969

end page

  • 972

volume

  • 38

issue

  • 5

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support